Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
PMVK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PMVK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PMVK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PKN3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PKN3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PKN3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PLK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PLK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PLK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PKN1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PKN1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PKN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PKN2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PKN2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PKN2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PLK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PLK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PLK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PKM Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PKM Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PKM sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PKLR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PKLR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PKLR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PITRM1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PITRM1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PITRM1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PIP5K1C Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PIP5K1C Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PIP5K1C sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PKMYT1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PKMYT1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PKMYT1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PINK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PINK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PINK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →